Drug Trial Radar · NCT02378480
Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)
Last checked: Nov 20, 2026Latest source record: Mar 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
655
Actual
Start
Jun 2015
Primary completion
Apr 2016
Study completion May 2016
Sponsor
- Lead sponsor
- Paratek Pharmaceuticals IncIndustry
- Sponsor type
- Industry
- First posted
- Mar 4, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to linezolid in the treatment of adults with acute bacterial skin and skin structure infections.
Conditions
- Bacterial Infections
- Skin Structures and Soft Tissue Infections
Interventions
OmadacyclineDrug
Injection for IV dosing; Tablets for oral dosing
LinezolidDrug
Infusion solution for IV dosing; Tablets for oral dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Early Clinical ResponseTime frame: Screening; 48 to 72 hours after the first dose of test article
Locations
78 sites in 14 countries. Site status is shown where the registry gives one.
Site 261
Mobile, Alabama
Site 262
Chula Vista, California
Site 254
La Mesa, California
Site 258
Oceanside, California
Site 252
Santa Ana, California
Site 260
Santa Ana, California
Site 269
Stockton, California
Site 259
Miami, Florida
Site 264
West Palm Beach, Florida
Site 256
Augusta, Georgia
Site 253
Columbus, Georgia
Site 257
Springfield, Massachusetts
Site 268
Detroit, Michigan
Site 266
Butte, Montana
Site 263
Las Vegas, Nevada
Site 270
Somers Point, New Jersey
Site 273
Buffalo, New York
Site 255
Rapid City, South Dakota
Site 104
Pleven, Bulgaria
Site 102
Plovdiv, Bulgaria
Site 105
Plovdiv, Bulgaria
Site 103
Rousse, Bulgaria
Site 101
Sofia, Bulgaria
Site 205
Slavonski Brod, Croatia
Site 201
Zagreb, Croatia
Site 203
Zagreb, Croatia
Site 202
Zagreb, Croatia
Site 204
Zagreb, Croatia
Site 207
Athens, Greece
Site 211
Athens, Greece
Site 208
Thessaloniki, Greece
Site 209
Thessaloniki, Greece
Site 110
Budapest, Hungary
Site 111
Budapest, Hungary
Site 114
Miskolc, Hungary
Site 113
Szeged, Hungary
Site 213
Holon, Israel
Site 219
Kfar Saba, Israel
Site 214
Nazareth, Israel
Site 216
Safed, Israel
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.